Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations

August 17, 2026

Allogene Therapeutics, Inc. (Press Release) USA

Overview

Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) negativity rate at a protocol-defined cutoff in the ALPHA3 Phase 2 trial for first-line large B-cell lymphoma (LBCL). This exceptional outcome led to FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. Furthermore, the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases is progressing well, showcasing the broad applicability of the company’s allogeneic CAR T platform.

In Depth

Key Findings

Allogene Therapeutics, in its second-quarter 2026 financial results, reported significant progress across its key clinical development programs. Notably, its off-the-shelf CAR T-cell therapy, cema-cel, achieved a high minimal residual disease (MRD) negativity rate of 58.3% at a protocol-defined cutoff in the ALPHA3 Phase 2 trial for first-line large B-cell lymphoma (LBCL). This groundbreaking achievement has been further underscored by the U.S. Food and Drug Administration (FDA) granting cema-cel both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. Additionally, the Phase 1 RESOLUTION trial for ALLO-329, being developed for autoimmune diseases, is progressing smoothly, highlighting the company’s expanding pipeline.

Technical / Clinical Details

Cema-cel is an anti-CD19 allogeneic CAR T-cell therapy, manufactured from donor-derived T-cells. This ‘off-the-shelf’ characteristic allows for rapid treatment initiation and potential cost reductions compared to conventional autologous CAR T-cell therapies, which require individual patient cell processing. The ALPHA3 trial evaluates the efficacy and safety of cema-cel in LBCL patients who show evidence of minimal residual disease after chemotherapy. MRD negativity is a critical biomarker indicating the absence of residual cancer cells post-treatment, and a high MRD negativity rate is strongly correlated with improved long-term disease-free survival (DFS). The 58.3% MRD negativity rate suggests potent anti-tumor activity for cema-cel in this patient population. The RMAT designation is designed to accelerate the development and review of innovative regenerative medicine products for serious conditions, while the Fast Track designation further implies expedited FDA review. ALLO-329, targeting new pathways in autoimmune diseases, demonstrates the expansion of CAR T technology beyond oncology.

Background & Context

Large B-cell lymphoma is one of the most common non-Hodgkin lymphomas, and there is a strong need for new treatment options, particularly for patient populations at high risk of relapse after first-line therapy. While conventional autologous CAR T-cell therapies are effective, their manufacturing process can take several weeks, posing a critical time constraint for severely ill patients. Allogene Therapeutics’ off-the-shelf CAR T-cells overcome this logistical challenge by providing immediate treatment when needed, potentially acting as a game-changer in areas with high unmet needs. Success in achieving MRD negativity indicates the depth and quality of the response, which could influence future clinical trial designs and treatment guidelines. Furthermore, the FDA’s RMAT and Fast Track designations signify regulatory recognition of cema-cel’s innovation and clinical significance, likely accelerating its approval process.

Strategic Significance & Outlook

The positive interim results from the ALPHA3 trial for cema-cel, coupled with multiple expedited review designations from the FDA, represent crucial milestones for Allogene Therapeutics. These developments indicate that the company is significantly closer to its goal of providing an off-the-shelf CAR T-cell therapy for first-line LBCL patients. Further disclosures of complete clinical data and ongoing dialogue with regulatory authorities are anticipated. Additionally, the progress of ALLO-329 for autoimmune diseases demonstrates the potential for CAR T technology to extend beyond oncology into broader therapeutic areas, forming a key component of Allogene Therapeutics’ long-term growth strategy. These advancements are expected to positively impact the broader cell therapy ecosystem, fostering the development of faster, more accessible advanced therapeutic options.

Source: https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2026-financial

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.